NAION: A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injections(s) To Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Grants and Contracts Details

StatusFinished
Effective start/end date3/16/16 → 2/12/20

Funding

  • Quark Pharmaceuticals Incorporated: $129,385.00